Page 110 - Read Online

Page 14 of 18 Franco et al. Hepatoma Res 2018;4:74 I http://dx.doi.org/10.20517/2394-5079.2018.94

ribavirin. N Engl J Med 2014;370:1594-603.
73. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic
hepatitis c virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis 2016;63:1479-81.
74. Grebely J, Puoti M, Wedemeyer H, Cooper CS, Sulkowski MS, et al. Safety and efficacy of ombitasvir, paritaprevir/ritonavir and
dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12
clinical trials. J Hepatol 2017;66:S514.
75. Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in
patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. Clin Infect Dis
2016;63:1405-11.
76. Read P, Lothian R, Chronister K, Gilliver R, Kearley J, et al. Delivering direct acting antiviral therapy for hepatitis C to highly
marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy 2017;47:209-15.
77. Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, et al. Understanding real-world adherence in the directly acting antiviral era: a
prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J
Drug Policy 2017;47:202-8.
78. Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, et al. Implementing and scaling up HCV treatment services for people
who inject drugs and other high risk groups in Ukraine: an evaluation of programmatic and treatment outcomes. Int J Drug Policy
2017;47:187-95.
79. Norton BL, Fleming J, Bachhuber MA, Steinman M, DeLuca J, et al. High HCV cure rates for people who use drugs treated with
direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy 2017;47:196-201.
80. Boglione L, Mornese Pinna S, De Nicolò A, Cusato J, Cariti G, et al. Treatment with direct-acting antiviral agents of hepatitis C virus
infection in injecting drug users: a prospective study. J Viral Hepat 2017;24:850-7.
81. Grebely J, Dalgard O, Conway B, Cunningham E, Bruggmann P, et al. Efficacy and safety of sofosbuvir/velpatasvir in people with
chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study. J Hepatol 2017;66:S513.
82. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Can antiviral therapy for hepatitis C reduce the prevalence of
HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011;54:1137-44.
83. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among
people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
Clin Infect Dis 2013;57:S39-45.
84. WHO. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Available from: http://apps.who.
int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf. [Last accessed on 28 Nov 2018]
85. AASLD/IDSA. HCV guidance: recommendations for testing, managing and treating hepatitis C. Available from: http://www.
hcvguidelines.org. [Last accessed on 28 Nov 2018]
86. EASL. Recommendations on treatment of hepatitis C. Available from: http://www.easl.eu/medias/cpg/HCV2016/English-report.pdf.
[Last accessed on 28 Nov 2018]
87. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, et al. Recommendations for the management of hepatitis C virus
infection among people who inject drugs. Intl J Drug Policy 2015;26:1028-38.
88. EASL. Sustained virological response to oral hepatitis C virus treatment associated with reduced mortality in an Italian cohort.
Available from: https://medicalxpress.com/news/2018-04-sustained-virological-response-oral-hepatitis.html. [Last accessed on 28 Nov
2018]
89. Infohep. Direct-acting antivirals bring fewer HCV-related liver transplants, better survival after transplantation, in Europe. Available
from: www.infohep.org/Direct-acting-antivirals-bring-fewer-HCV-related-liver-transplants-better-survival-after-transplantation-in-
Europe/page/3257600/. [Last accessed on 28 Nov 2018]
90. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, et al.The global burden of viral hepatitis from 1990 to 2013: findings
from the global burden of disease study 2013. Lancet 2016;388:1081-8.
91. Konerman MA, Lok ASF. Hepatitis c treatment and barriers to eradication. Clin Transl Gastroenterol 2016;7:e193.
92. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to
continuum to control. Clin Infect Dis 2013;57:1164-71.
93. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013;368:1859-61.
94. Stein JA, Andersen RM, Robertson M, Gelberg L. Impact of hepatitis B and C infection on health services utilization in homeless
adults: a test of the Gelberg-Andersen behavioral model for vulnerable populations. Health Psychol 2012;31:20-30.
95. Desai RA, Rosenheck RA, Agnello V. Prevalence of hepatitis C virus infection in a sample of homeless veterans. Soc Psychiatry
Psychiatr Epidemiol 2003;38:396-401.
96. Nyamathi AM, Dixon EL, Robbins W, Smith C, Wiley D, et al. Risk factors for hepatitis C virus infection among homeless adults. J
Gen Intern Med 2002;17:134-43.
97. Stein JA, Nyamathi A. Correlates of hepatitis C virus infection in homeless men: a latent variable approach. Drug Alcohol Depend
2004;75:89-95.
98. Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol 2013;19:6703-9.
99. Grundy G, Beeching N. Understanding social stigma in women with hepatitis C. Nurs Stand 2004;19:35-9.
100. Paterson BL, Backmund M, Hirsch G, Yim C. The depiction of stigmatization in research about hepatitis C. Int J Drug Policy
2007;18:364-73.
101. Schäfer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C.
Addiction 2000;95:1101-4.
102. Bogart LM, Cowgill BO, Kennedy D, Ryan G, Murphy DA, et al. HIV-related stigma among people with HIV and their families: a